Université de Lorraine, Inserm, Centre d'Investigations Cliniques, Plurithématique 1433, and Inserm 1116 DCAC, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
Emergency Department, Centre Hospitalier Régional Metz-Thionville, Metz, France.
ESC Heart Fail. 2020 Oct;7(5):2042-2050. doi: 10.1002/ehf2.12834. Epub 2020 Jun 29.
How general practitioners (GPs) manage dyskalaemia is currently unknown. This study aimed at describing GP practices regarding hypokalaemia or hyperkalaemia diagnosis and management in their outpatients.
A telephone survey was conducted among French GPs with a 20-item questionnaire (16 closed-ended questions and 12 open-ended questions) regarding their usual management of hypokalaemia or hyperkalaemia patients, both broadly and more specifically in patients with heart failure and/or chronic kidney disease and/or in patients treated with angiotensin-converting enzyme/angiotensin receptor blockers or mineralocorticoid receptor antagonists. We aimed to interview 500 GPs spread geographically throughout France. This descriptive survey results are presented as mean ± standard deviation (if normally distributed or as median and inter-quartile range if the distribution was skewed). Categorical variables are expressed as frequencies and proportions (%). A total of 500 GPs participated in the study. Dyskalaemia thresholds (for diagnosis and intervention) and management patterns were highly heterogeneous. The mean ± SD (range) potassium level leading to 'intervene' was 5.32 ± 0.34 mmol/L (4.5-6.5) for hyperkalaemia and 3.23 ± 0.34 mmol/L (2.0-6.5) for hypokalaemia. Potassium levels leading to refer the patient to the emergency department (ED) were 6.14 ± 0.55 (4.5-10) and 2.69 ± 0.42 mmol/L (1-4), respectively. Potassium binders (51-65%) or potassium supplements (67-74%) were frequently used to manage hyperkalaemia or hypokalaemia. GPs uncommonly referred their dyskalaemic patients to cardiologists or nephrologists (or to the emergency department, if the latter was deemed necessary owing to the severity of the dyskalaemia). We identified an association between the close vicinity of GP office from an ED and 'referring a heart failure patient' (19.2% with ED vs. 8.6% without ED) and referring a heart failure and chronic kidney disease patient on mineralocorticoid receptor antagonist (16.7% with ED vs. 9.3% without ED). Although the majority (67%) of GPs had an electrocardiogram on hand, it was rarely used (14%) in dyskalaemic patients. Subgroup analyses considering gender, age of the participating GPs, and high-income/low-income regions did not identify specific patterns regarding the multidimensional aspect of dyskalaemia management.
Owing to the considerable heterogeneity of French GP practices toward dyskalaemia diagnosis and management approaches, there is a likely need to standardize (potentially enabled by therapeutic algorithms) practices.
目前尚不清楚全科医生(GP)如何处理电解质紊乱。本研究旨在描述 GP 门诊低钾血症或高钾血症的诊断和管理实践。
对法国 GP 进行了一项电话调查,使用了一份包含 20 个项目的问卷(16 个封闭式问题和 12 个开放式问题),内容涉及他们对低钾血症或高钾血症患者的常规管理,包括广泛的管理以及心力衰竭和/或慢性肾脏病患者以及接受血管紧张素转换酶/血管紧张素受体阻滞剂或盐皮质激素受体拮抗剂治疗的患者的更具体管理。我们的目标是在法国各地的 500 名 GP 中进行采访。该描述性调查结果以平均值±标准差(如果呈正态分布)或中位数和四分位距(如果分布偏斜)表示。分类变量以频率和比例(%)表示。共有 500 名 GP 参与了这项研究。电解质紊乱的阈值(用于诊断和干预)和管理模式高度多样化。高钾血症时导致“干预”的平均±SD(范围)血钾水平为 5.32±0.34mmol/L(4.5-6.5),低钾血症时为 3.23±0.34mmol/L(2.0-6.5)。导致患者转至急诊部(ED)的血钾水平分别为 6.14±0.55(4.5-10)和 2.69±0.42mmol/L(1-4)。经常使用钾结合剂(51-65%)或钾补充剂(67-74%)来治疗高钾血症或低钾血症。GP 很少将电解质紊乱患者转介给心脏病专家或肾病专家(如果由于电解质紊乱的严重程度需要转介到 ED)。我们发现 GP 办公室与 ED 的距离与“转介心力衰竭患者”之间存在关联(ED 附近的 GP 为 19.2%,无 ED 的 GP 为 8.6%),并与 ED 附近的心力衰竭和慢性肾脏病患者以及接受盐皮质激素受体拮抗剂治疗的患者存在关联(ED 附近的 GP 为 16.7%,无 ED 的 GP 为 9.3%)。尽管大多数(67%)GP 都有心电图,但在电解质紊乱患者中很少使用(14%)。考虑到参与 GP 的性别、年龄以及高收入/低收入地区的亚组分析,并未发现针对电解质紊乱管理多维方面的特定模式。
由于法国 GP 在电解质紊乱的诊断和管理方法方面存在相当大的差异,因此可能需要进行标准化(可能通过治疗算法实现)。